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Neuroleptic Malignant Syndrome, with
Attention to Its Occurrence with Atypical
Antipsychotic Medication: A Review
Sarah Guzofski, M.D. (PGY2), Ruben Peralta, M.D.

ABSTRACT
The neuroleptic malignant syndrome (NMS) is an idiopathic, life-threatening reaction to
antipsychotic medication.
NMS was traditionally attributed to potent dopamine
antagonism of typical antipsychotics, but cases of NMS have now been reported for each of
the newer antipsychotics. When NMS is caused by a newer, atypical antipsychotic the
presentation differs somewhat; fever, rigidity, and, possibly, death may be less frequent.
Diagnostic features, predisposing factors, and treatment are discussed, as is the important
matter of reinstituting antipsychotic treatment.

Neuroleptic malignant syndrome (NMS) is an idiosyncratic, life-threatening
reaction to antipsychotic medication, characterized principally by delirium, fever,
autonomic instability, and muscular rigidity (1). Most cases occur within a month
of starting the medication, two-thirds within the first week. NMS develops in 0.022.44 percent of patients who are prescribed antipsychotics (2-4); NMS may occur
even when doses are in the therapeutic range; the risk is somewhat greater with
rapid dose escalation and with parenteral administration.
Hyperthermia, delirium, autonomic instability, and extrapyramidal symptoms in
a person treated with antipsychotic medications should prompt consideration of
NMS. Classically, the extrapyramidal symptoms of NMS manifest as “lead pipe”
rigidity of the limbs; other extrapyramidal signs, such as tremor, and cogwheeling,
may be present. The muscular rigidity leads to rhabdomyolysis, which can in turn
result in renal failure. A wide range of mental status presentations are possible, but
patients are most often mute and stuporous.
Laboratory findings include
leukocytosis (most often 10-20,000, thought to be a stress response) elevated
creatine kinase (can reach 100,000), hypocalcemia (from muscle sequestration of
calcium), moderate elevations of LDH, AST and ALT, and elevated serum
osmolarity from dehydration. An EEG may show generalized slowing, consistent
with delirium (5). Symptoms generally develop over 24-72 hours and, in
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uncomplicated cases, the mean duration of symptoms is 13-15 days, longer if
caused by a depot medication (2). Serious complications are possible, including
renal failure, thromboembolism, respiratory failure from chest wall rigidity,
aspiration pneumonia, and arrhythmia (5).
DSM IV-TR criteria (6) for diagnosing NMS are in Table 1. A slightly different
set of criteria, proposed by Levenson (5), is also commonly employed (Table 2).

Table 1. DSM IV-TR Diagnostic Criteria for NMS
Severe muscle rigidity and elevated temperature associated with the use of neuroleptic
medication as well as 2 or more of the following
Diaphoresis
Dysphagia
Tremor
Incontinence
Changes in level of consciousness ranging from confusion to coma
Mutism
Tachycardia
Elevated or labile blood pressure
Leukocytosis
Laboratory evidence of muscle injury

Table 2. Levenson’s criteria for the diagnosis of NMS*
Major criteria
fever
rigidity
elevated creatine kinase (CK)
Minor criteria
tachycardia
abnormal blood pressure
altered consciousness
diaphoresis
leukocytosis
* 3 major criteria, or 2 major and 4 minor criteria, are required for diagnosis

In the differential diagnosis, infectious, metabolic and neurologic conditions
should be considered, depending on associated clinical features (Table 3). An
interesting debate has centered around the similarities and differences between
malignant catatonia and NMS. These two conditions, affecting a similar patient
population, can be so similar in their presenting features that some have argued
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that they are variants on a spectrum (7). Because NMS, malignant catatonia, and
serotonin syndrome are difficult to distinguish on symptomatic presentation alone,
medication history, behavioral prodrome, and timeline of symptom-evolution will
be critical to making a diagnosis.
Table 3. Differential Diagnosis
Diagnosis
Infectious: meningitis,
encephalitis, bacteremic sepsis
Metabolic: thyrotoxicosis,
pheochromocytoma
Neurologic: nonconvulsive
status epilepticus, postictal
state
Drug intoxications: MDMA,
cocaine, amphetamines
Serotonin syndrome

Lithium toxicity
Central anticholinergic
syndrome
Malignant hyperthermia
Malignant or lethal catatonia

Neuroleptic-induced heat
stroke

Suggestive Clinical Features, Indicated Lab Testing
Lumbar puncture. Consider blood and urine cultures
depending on overall clinical picture
Check TSH, urine catacholamines and metanephrines
EEG

Urine toxicology
Associated with gastrointestinal signs and symptoms
(hyperactive bowel sounds, diarrhea, vomiting), myoclonus,
hyperreflexia
Check lithium level. Myoclonus, hyperreflexia, tremor
Dry, flushed skin, diminished sweating, urinary retention,
dilated pupils
Exposure to halogenated anesthetics
Associated with hyperpyrexia, rigidity, akinesia. Review
behavior changes over previous weeks. May be preceded
by emotional withdrawal, anxiety, agitation, stereotypies,
posturing, waxy flexibility, mutism.
Suggestive history: warm environment, abrupt onset, no
extrapyramidal signs, may have absence of diaphoresis if
anticholinergic properties interfere with sweating.

Risk Factors
NMS is an idiosyncratic reaction and cannot be predicted, but there are some
identified risk factors. Young age, male gender, dehydration, agitation, rapid doseescalation, and intra-muscular administration increase the risk (5,8). Prior NMS
increases the risk for future episodes. There is some evidence for an association
between NMS and the following (9,10): concurrent lithium treatment, poorly
controlled extrapyramidal symptoms, patients with affective disorders, iron
deficiency, poor nutrition, environmental heat load, catatonia, and those drugs that
are more potent dopamine-2 (D2) antagonists.
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Pathogenesis
The pathogenesis of NMS is unknown. Observation that NMS occurred with D2
blocking agents lead to the hypothesis that D2 blockade in various regions of the
brain explained the presentation: D2 action in the reticular activating system could
cause changes in level of consciousness; D2 blockade in the nigrostriatal pathway
could cause rigidity; D2 blockade in the hypothalamus could account for
autonomic instability and impaired heat dissipation, thus hyperpyrexia from the
combination of hypothalamic dysfunction and muscle rigidity (9-11). This theory
is now challenged since atypical antipsychotics, with their lower D2 potency, are
reported to cause NMS.
NMS and Atypical Antipsychotics
There have been reports of NMS attributed to each of the atypical antipsychotics
and all of these medications are listed in the NMS Information Services’ Registry
(9). The rates and presenting symptoms of NMS in typical versus atypical
antipsychotics have not been directly compared (12), but some observations are
possible from available information. Of the 55 “probable” or “definite” cases of
NMS reported to the Neuroleptic Malignant Syndrome Information Service
between 1998 and 2002, 31 patients (56%) were on a typical antipsychotic; 24
patients (44%) were on an atypical antipsychotic (13). Cases of NMS have been
reported with even the least potent D2 antagonist, clozapine (2,14).
NMS owing to atypical antipsychotics has possibly a different presentation
compared with the traditional syndrome: less extreme CK and temperature
elevations and less common and milder rigidity (14,15). A 2003 review of 68
reported cases of NMS from atypical antipsychotics found that the mean peak CK
was 5958 and the mean maximum temperature was 38.8. Seventy eight percent of
patients had extrapyramidal symptoms. Twelve of the 68 required intensive care
and 3 patients died (2). This mortality rate is less than that historically reported in
NMS (11,16). Perhaps resulting from improved supportive care, mortality in NMS
is declining overall: from 76% prior to 1970 to 11% in a 1989 study, (2,11,17).
Treatment
If NMS is suspected, immediately discontinue all antipsychotic medication, as
well as other D2 blocking agents. A medical work-up should be initiated (see
above): NMS is a diagnosis of exclusion. Supportive care is the mainstay of
treatment for NMS and it should occur in a setting in which blood pressure,
cardiac rhythm, and pulse-oximetry can be continuously monitored. Autonomic
instability may manifest as hypertension, hypotension, tachycardia, or cardiac
arrhythmia. Chest wall rigidity can compromise respiration sufficiently to require
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intubation; intubation may also be indicated for severe aspiration pneumonia.
Urine alkalinization and adequate support with intravenous fluids may prevent
renal failure from myoglobinuria (18). Hyperthermia may require a cooling
blanket. Because hyperthermia in NMS is not mediated by pyrogens, antipyretic
medications are generally not helpful (1). Laryngeal dystonia, dysphagia,
respiratory distress, or delirium may preclude oral intake, so intravenous fluid and
parenteral nutrition may be needed (1). Prophylactic measures for deep venous
thrombosis and frequent repositioning will decrease the likelihood of
complications from rigidity and prolonged immobility (5). The medication list
should be reviewed: anticholinergic agents or other drugs that interfere with heat
dissipation should be discontinued (1).
Medication may hasten response to supportive therapy and decrease mortality
(19,20), but controlled clinical trials do not exist, and drug studies that are
available have not always shown benefit (21). The two most commonly used
pharmacologic interventions are bromocriptine, a central dopamine agonist, and
dantrolene, which facilitates skeletal muscle relaxation via calcium release from
the sarcoplasmic reticulum (5,9,22). Dantrolene is available in a parenteral form;
bromocriptine can only be administered orally. Symptoms of NMS sometimes
return if treatment is discontinued before complete clearance of the offending
medication, so, if bromocriptine, dantrolene, or both are utilized, treatment should
be continued for ten days beyond the resolution of symptoms, or for 2-3 weeks if
the offending agent has been an extended release depot antipsychotic (5).
Oral or intravenous benzodiazepine, the mainstay of early treatment of catatonia,
may decrease fever and rigidity in NMS, in addition to treating agitation (1).
Respiratory status should be monitored. Positive results have been reported with
diazepam (23) and lorazepam (24).
Electroconvulsive therapy (ECT) is another treatment option and may decrease
hyperpyrexia, diaphoresis, and delirium, possibly by modulating dopamine activity
in the brain. Onset of response, on average, is after 4 treatments (12). ECT should
be considered especially for patients who have not improved after 48 hours of
pharmacologic treatment, if it is not clear whether the cause of the symptoms is
neuroleptic malignant syndrome or malignant catatonia, and if the underlying
psychiatric diagnosis is a mood disorder (12,25-28).
Antipsychotic treatment after NMS
Patients with a history of NMS are likely to require future antipsychotic
treatment. The estimated risk of developing NMS again with repeat exposure to a
D2 blocker is 30%, and the risk of mortality from subsequent NMS episodes is
estimated to be as high as 20%) (13). Treatment decisions are further complicated
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by the observation that not all patients will experience a recurrence, even if they
are treated with the same drug.
There are very few formal studies documenting the outcome of antipsychotic
treatment after NMS. Several reviews of this topic were written in the late 1980s
(28-30, 32). For example, Olmstead reviewed 29 rechallenges reported in the
literature; 13 of the 29 had a recurrence, and 2 of those patients died; the most
common agent used for rechallenge was the low potency agent thioridazine (13 of
29 patients, causing 2 recurrences of NMS, one culminating in death) (29).
Rechallenges that produce recurrence of NMS are reported with a variety of
medications. Rechallenge at least 2 weeks after the initial episode appears to be
safer, and recurrence is more likely if high potency medication or high doses are
used (1). In a 1989 review, Rosebush and colleagues report that 13 of 15 patients
with prior NMS experienced no recurrence on rechallenge (30). And two small,
longer-term reviews found that in a majority of patients who are rechallenged with
antipsychotic medication NMS does not recur (31,32).
Based on these reviews, on the observed risk factors for NMS, and on theoretical
speculation about pathogenesis, we come to the following as recommendations for
reinstituting treatment after the first episode, with the understanding that the
evidence supporting them is limited. Weigh risks, benefits, and alternatives to
antipsychotic medication. If alternatives are poor and the benefit outweighs the
risk, restart antipsychotic after a 4-week waiting period following the resolution of
the episode. Begin with a low dose, advance slowly toward the target dose, and
choose an agent with low D2-nigrostriatal affinity (an atypical or a low potency
typical). Monitor carefully for fever, autonomic instability, mental status change,
extrapyramidal symptoms, and dehydration. Serial measurements of white blood
cell count and CK are warranted. Agitation should be treated aggressively with
benzodiazepine, since agitation increases the risk for NMS. Adjunctive treatment
with a mood stabilizer, antidepressant, or both for affective symptoms may
minimize, possibly, the required dose of antipsychotic (22,29,33). Velamoor has
suggested considering prophylaxis with amantadine or bromocriptine (22).
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